Literature DB >> 34923659

Overdiagnosis of hepatocellular carcinoma: Prevented by guidelines?

Nicole E Rich1, Amit G Singal1.   

Abstract

Overdiagnosis refers to detection of disease that would not otherwise become clinically apparent during a patient's lifetime. Overdiagnosis is common and has been reported for several cancer types, although there are few studies describing its prevalence in HCC surveillance programs. Overdiagnosis can have serious negative consequences including overtreatment and associated complications, financial toxicity, and psychological harms related to being labeled with a cancer diagnosis. Overdiagnosis can occur for several different reasons including inaccurate diagnostic criteria, detection of premalignant or very early malignant lesions, detection of indolent tumors, and competing risks of mortality. The risk of overdiagnosis is partly mitigated, albeit not eliminated, by several guideline recommendations, including definitions for the at-risk population in whom surveillance should be performed, surveillance modalities, surveillance interval, recall procedures, and HCC diagnostic criteria. Continued research is needed to further characterize the burden and trends of overdiagnosis as well as identify strategies to reduce overdiagnosis in the future.
© 2021 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2022        PMID: 34923659      PMCID: PMC8844206          DOI: 10.1002/hep.32284

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  144 in total

1.  Overdiagnosis: what it is and what it isn't.

Authors:  John Brodersen; Lisa M Schwartz; Carl Heneghan; Jack William O'Sullivan; Jeffrey K Aronson; Steven Woloshin
Journal:  BMJ Evid Based Med       Date:  2018-02

2.  Length time bias in surveillance for hepatocellular carcinoma and how to avoid it.

Authors:  Alessandro Cucchetti; Francesca Garuti; Antonio Daniele Pinna; Franco Trevisani
Journal:  Hepatol Res       Date:  2016-03-30       Impact factor: 4.288

3.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

4.  Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes.

Authors:  Neil Mehta; Jennifer L Dodge; John P Roberts; Ryutaro Hirose; Francis Y Yao
Journal:  Hepatology       Date:  2019-02-10       Impact factor: 17.425

5.  Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance.

Authors:  Natalia Khalaf; Jun Ying; Sahil Mittal; Sarah Temple; Fasiha Kanwal; Jessica Davila; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2016-08-10       Impact factor: 11.382

6.  Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review.

Authors:  Christian B van der Pol; Christopher S Lim; Claude B Sirlin; Trevor A McGrath; Jean-Paul Salameh; Mustafa R Bashir; An Tang; Amit G Singal; Andreu F Costa; Kathryn Fowler; Matthew D F McInnes
Journal:  Gastroenterology       Date:  2018-11-13       Impact factor: 22.682

7.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

8.  International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma.

Authors:  Amit G Singal; Yujin Hoshida; David J Pinato; Jorge Marrero; Jean-Charles Nault; Valerie Paradis; Nabihah Tayob; Morris Sherman; Young Suk Lim; Ziding Feng; Anna S Lok; Jo Ann Rinaudo; Sudhir Srivastava; Josep M Llovet; Augusto Villanueva
Journal:  Gastroenterology       Date:  2021-03-09       Impact factor: 33.883

9.  Benefits and Harms of Hepatocellular Carcinoma Surveillance in a Prospective Cohort of Patients With Cirrhosis.

Authors:  Amit G Singal; Sruthi Patibandla; Joseph Obi; Hannah Fullington; Neehar D Parikh; Adam C Yopp; Jorge A Marrero
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-10       Impact factor: 13.576

10.  Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.

Authors:  Amit G Singal; Anjana Pillai; Jasmin Tiro
Journal:  PLoS Med       Date:  2014-04-01       Impact factor: 11.069

View more
  2 in total

1.  Disparities in curative treatments and outcomes for early stage intrahepatic cholangiocarcinoma in the United States.

Authors:  Yi-Te Lee; Amit G Singal; Marie Lauzon; Vatche G Agopian; Michael Luu; Mazen Noureddin; Tsuyoshi Todo; Irene K Kim; Marc L Friedman; Kambiz Kosari; Nicholas N Nissen; Lewis R Roberts; Julie K Heimbach; Gregory J Gores; Ju Dong Yang
Journal:  Cancer       Date:  2022-08-23       Impact factor: 6.921

2.  Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort.

Authors:  Neehar D Parikh; Nabihah Tayob; Taim Al-Jarrah; Jennifer Kramer; Jennifer Melcher; Donna Smith; Patrick Marquardt; Po-Hong Liu; Runlong Tang; Fasiha Kanwal; Amit G Singal
Journal:  JAMA Netw Open       Date:  2022-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.